Skip to main content
Caplight Logo









Odyssey Therapeutics

Odyssey Therapeutics

Public
Boston, MassachusettsBiotechhttps://odysseytx.com/

Odyssey Therapeutics is now publicly traded

The data on this page reflects Odyssey Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

May 7, 2026

Last Round

Series D

Sep 10, 2025

Total Funding Raised

$1.11B

Company Overview

Odyssey Therapeutics is a biotechnology company that develops precision immunomodulators and oncology medicines to treat autoimmune and inflammatory diseases.

Sector

Biotech

AI Layer

Application

Keywords

small molecule drug discoveryprecision medicineAI-driven drug discoverybiotechdrug discovery platformoncology pipelineimmunologycomputational chemistryin silico drug designbiopharmatherapeutic candidatesdrug developmentAI-first biotechsmall molecule inhibitorsbiotech startup

Odyssey Therapeutics Comparables

Compare Odyssey Therapeutics with similar companies based on industry and business-model similarity.

Odyssey Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Treeline Biosciences
89%
Eikon Therapeutics
81%
Mirador Therapeutics
80%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Odyssey Therapeutics Funding Rounds

Historical fundraising activity

Book a demo to see all 6 rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Gary D. Glick

Founder And CEO

Founding Team

Jason Haas

Chief Financial Officer

Executive Team

For institutional investors. Book with your work email.

Odyssey Therapeutics Investors

Notable investors and investment history

Odyssey Therapeutics investors
InvestorRounds
GreatPoint VenturesSeries B
CPP InvestmentsSeries C
Wedbush Healthcare PartnersSeries D
KB InvestmentSeries C
Frontline BioVenturesSeries B, Series C, Series A
KB InvestmentSeries C
Creacion VenturesSeries B, Series C, Series A, Series D
Book a demo to see all investors

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • has_revenueNov 6, 2026

    Odyssey Therapeutics, Inc. generates $100K in revenue in the latest fiscal quarter, matching the prior-year quarter.

Book a demo to see all news

For institutional investors. Book with your work email.

Odyssey Therapeutics Filings

Explore SEC and related filing metadata, where available.

Odyssey Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range117
Year Founded2021
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?